Info

Diffusion Pharmaceuticals LLC is a drug discovery and development company that owns a platform technology of patented small molecules which treat serious medical conditions by increasing tissue oxygenation. Human clinical trials for the Company's lead molecule trans sodium crocetinate (TSC) are targeted for 2005 for treatment of hemorrhagic shock. The company's pipeline drugs, known as trans bipolar carotenoid or TBC molecules, are currently in the pre-clinical stage in laboratories across the country for the treatment of severe blood loss, brain trauma, ischemic stroke, myocardial infarction, and other conditions characterized by oxygen deprivation at the cellular level. Diffusion Pharmaceuticals, which is privately held, is located in Charlottesville, Virginia, an emerging biotech and drug development center. For more, visit www.diffusionpharma.com.